Naozumi Harada

This inventor holds 5 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Kyoto University, Mie University, General Incorporated Association Pharma Valley Project Supporting Organization. Active years: 2021-2026.

USPTO Granted Patents = 5 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Tsu, JP (2021 - 2022)
Mie, JP (2024)

Company Filing History:

General Incorporated Association Pharma Valley Project Supporting Organization

patents

4. 1 out of 215

Kabushiki Kaisha Yakult Honsha

patents

5. 1 out of 1

United Immunity, Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12569562 - PRETREATMENT DRUG FOR T CELL INFUSION THERAPY FOR IMMUNE-CHECKPOINT INHIBITOR-RESISTANT TUMOR (2026-03-10),

2. 12059471 - Complex (2024-08-13),

3. 11213538 - Agent for overcoming immunosuppression and use thereof (2022-01-04),

4. 11179450 - Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells (2021-11-23),

5. 11083744 - Therapeutic agent associated with suppression of proliferation and metastasis of tumor, which comprises exosomes released from cytotoxic T cells and targets cancer stromal/mesenchymal cells (2021-08-10),

Title: Naozumi Harada: Innovator in Immunology and Oligonucleotide Technology

Introduction

Naozumi Harada is a prominent inventor based in Tsu, Japan. He has made significant contributions to the fields of immunology and oligonucleotide technology. With a total of 5 patents, his work focuses on developing innovative solutions to complex biological challenges.

Latest Patents

Harada's latest patents include a technique for forming CpG oligonucleotides and hydrophobized polysaccharides into complexes. This invention aims to provide a complex comprising a modified CpG oligonucleotide containing a hydrophobic group A with a sterol skeleton, and a modified polysaccharide containing a hydrophobic group B. Another notable patent is an agent for overcoming immunosuppression, which can counteract the effects of regulatory T cells. This agent includes an anthracycline antibiotic as an active ingredient, showcasing Harada's commitment to advancing medical science.

Career Highlights

Throughout his career, Harada has worked with esteemed institutions such as Kyoto University and Mie University. His research has significantly impacted the understanding and treatment of immunological conditions, making him a valuable asset in the scientific community.

Collaborations

Harada has collaborated with notable colleagues, including Hiroshi Shiku and Kazunari Akiyoshi. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Naozumi Harada's contributions to the fields of immunology and oligonucleotide technology are noteworthy. His innovative patents and collaborations reflect his dedication to advancing scientific knowledge and improving health outcomes.